kabutan

ASKA Pharmaceutical Holdings Co.,Ltd., First Half Ordinary Profit Increases by 7%

Tue Nov 5, 2024 3:30 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE-P] announced its financial results after the market closed on November 5th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) increased by 7.0% from the same period last year, reaching 3.31 billion yen. However, The progress rate against the 6.7 billion yen full-year plan was 49.4%, also falling below the five-year average of 54.9%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to decrease by 1.1% from the same period last year to 3.38 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit grew by 16.5% from the same period last year, reaching 1.49 billion yen. The operating profit margin improved from 8.6% in the same period last year to 9.9%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 30,172 2,879 2,987 2,346 83.2 57.1 Nov 7, 2022 J-GAAP
Apr - Sep, 2023 31,648 3,055 3,096 4,129 145.9 47.5 Nov 6, 2023 J-GAAP
Apr - Sep, 2024 32,371 3,345 3,312 2,560 90.4 49.4 Nov 5, 2024 J-GAAP
YoY +2.3% +9.5% +7.0% -38.0% -38.1%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance ー ー ー ー － 25 May 10, 2024 J-GAAP
Apr - Sep, 2024 Results 32,371 3,345 3,312 2,560 90.4 25 Nov 5, 2024 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 31,195 3,445 3,426 3,416 120.7 20 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 30,629 3,355 3,388 2,440 86.0 25 Nov 5, 2024 J-GAAP
YoY -1.8% -2.6% -1.1% -28.6% -28.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 60,461 5,108 5,232 4,238 150.1 16 May 11, 2023 J-GAAP
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 Guidance 63,000 6,700 6,700 5,000 176.3 50 May 10, 2024 J-GAAP
YoY +0.2% +3.1% +2.7% -33.7% -33.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 15,625 1,351 1,287 2,701 95.5 8.6 Nov 6, 2023 J-GAAP
Oct - Dec, 2023 17,176 2,471 2,535 2,329 82.3 14.4 Feb 5, 2024 J-GAAP
Jan - Mar, 2024 14,019 974 891 1,087 38.4 6.9 May 10, 2024 J-GAAP
Apr - Jun, 2024 16,352 1,758 1,813 1,273 45.0 10.8 Aug 5, 2024 J-GAAP
Jul - Sep, 2024 16,019 1,587 1,499 1,287 45.4 9.9 Nov 5, 2024 J-GAAP
YoY +2.5% +17.5% +16.5% -52.4% -52.4%

Related Articles